Veru (NASDAQ:VERU) Shares Pass Below 200 Day Moving Average – Should You Sell?

Veru Inc. (NASDAQ:VERU) shares crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $0.81 and traded as low as $0.64. Veru shares last traded at $0.68, with a volume of 1,431,955 shares changing hands.

Wall Street Analysts Forecast Growth

VERU has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $3.00 target price on shares of Veru in a research report on Friday, December 20th. Oppenheimer reissued an “outperform” rating and issued a $5.00 price objective on shares of Veru in a research note on Tuesday, November 5th.

Veru Stock Down 1.3 %

The stock has a market capitalization of $98.93 million, a P/E ratio of -1.41 and a beta of -0.50. The business’s 50 day simple moving average is $0.72 and its two-hundred day simple moving average is $0.81.

Veru (NASDAQ:VERU) last issued its quarterly earnings data on Monday, December 16th. The company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.07) by $0.01. Veru had a negative return on equity of 115.99% and a negative net margin of 376.38%. Analysts predict that Veru Inc. will post -0.3 earnings per share for the current year.

Institutional Investors Weigh In On Veru

Institutional investors have recently bought and sold shares of the stock. Zacks Investment Management purchased a new position in Veru during the 3rd quarter worth $25,000. Gladstone Institutional Advisory LLC raised its holdings in shares of Veru by 34.2% in the third quarter. Gladstone Institutional Advisory LLC now owns 56,876 shares of the company’s stock valued at $44,000 after purchasing an additional 14,500 shares during the last quarter. SG Americas Securities LLC lifted its position in shares of Veru by 185.9% during the third quarter. SG Americas Securities LLC now owns 66,128 shares of the company’s stock valued at $51,000 after purchasing an additional 42,997 shares in the last quarter. Jane Street Group LLC boosted its holdings in Veru by 142.8% during the third quarter. Jane Street Group LLC now owns 96,454 shares of the company’s stock worth $74,000 after purchasing an additional 56,736 shares during the last quarter. Finally, Rhumbline Advisers grew its position in Veru by 3,994.8% in the 2nd quarter. Rhumbline Advisers now owns 113,632 shares of the company’s stock worth $96,000 after purchasing an additional 110,857 shares in the last quarter. Institutional investors own 47.16% of the company’s stock.

About Veru

Veru Inc, a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its marketed products comprise FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections.